GLP-1 Weight-Loss Medications: What to Know About Wegovy, Zepbound, and Medically Guided Care
Few areas of medicine have changed as quickly as obesity treatment. Prescription medications such as semaglutide (Wegovy) and tirzepatide (Zepbound) can help many adults lose a meaningful amount of weight and improve related health conditions. They are not right for everyone, and they work best as part of a supervised plan. Here is what to know, from Meridian Weight Loss & Metabolic Health.
What are GLP-1 medications?
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural hormone that helps regulate appetite and blood sugar. They slow stomach emptying and act on appetite centers in the brain, so many people feel full sooner and have fewer cravings. Tirzepatide also acts on a second hormone pathway (GIP).
FDA-approved options for chronic weight management
- Wegovy (semaglutide 2.4 mg) was approved by the FDA in June 2021 for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity (FDA announcement).
- Zepbound (tirzepatide) was approved by the FDA in November 2023 for chronic weight management under similar criteria (approval history).
Ozempic and Mounjaro contain the same active ingredients but are FDA-approved for type 2 diabetes, not specifically for weight management.
What results do studies show?
In the STEP 1 clinical trial published in the New England Journal of Medicine, adults with overweight or obesity who took weekly semaglutide 2.4 mg along with lifestyle support lost an average of about 14.9% of their body weight over 68 weeks, compared with about 2.4% in the placebo group (NEJM, 2021). Individual results vary, and weight can return if the medication is stopped without a long-term plan.
Common side effects and safety considerations
- The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually most noticeable when starting or increasing the dose.
- These medications are not appropriate for everyone, including people with a personal or family history of certain thyroid cancers (medullary thyroid carcinoma) or MEN 2 syndrome, and they are not used during pregnancy.
- Your clinician will review your medical history, current medications, and lab results before prescribing, and will monitor you over time.
A note on compounded and online versions
The FDA has warned that unapproved and compounded GLP-1 products do not undergo FDA review for safety, effectiveness, and quality, and it has received reports of adverse events, including dosing errors that led to hospitalization (FDA). Always get these medications through a licensed prescriber and a reputable pharmacy.
Why medically guided care matters
Medication is one tool. Lasting results usually come from combining it with nutrition, physical activity, sleep, stress management, and follow-up. At Meridian, Dr. Albert E. Takem, who is board certified in Internal Medicine and Obesity Medicine, leads individualized weight-management care that is coordinated with primary care and laboratory testing. For more on nutrition basics, read Why Nutrition Matters for Your Overall Health.
Want to hear more? Dr. Takem discusses common GLP-1 questions, such as weight regain after stopping medication and muscle loss, on the Daily Brief Podcast.
Frequently asked questions
Who may qualify for a GLP-1 weight-loss medication?
FDA labeling generally covers adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes. Your clinician will help determine whether it is appropriate for you.
Will insurance cover it?
Coverage varies widely by plan. Our Financial & Billing Guide explains how to check your benefits.
Will I gain weight back if I stop?
Some weight regain is common after stopping. Your care team can help you plan for the long term, including nutrition, activity, and follow-up.
Explore medically guided weight management
Talk with Meridian about whether medication, lifestyle support, or both are right for you.
Sources
- U.S. FDA – FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 (June 2021)
- Drugs.com – Zepbound (tirzepatide) FDA Approval History
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021
- U.S. FDA – FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
This article is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. If you have a medical emergency, call 911. If you are in crisis or thinking about suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline.
Leave a reply
